Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Trends in antiretroviral drug use during pregnancy among HIV-infected women on medicaid: 2000-2007.

Phiri K, Fischer MA, Mogun H, Williams PL, Palmsten K, Seage GR 3rd, Hernandez-Diaz S.

AIDS Patient Care STDS. 2014 Feb;28(2):56-65. doi: 10.1089/apc.2013.0165.

2.

Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.

Phiri K, Williams PL, Dugan KB, Fischer MA, Cooper WO, Seage GR 3rd, Hernandez-Diaz S.

Pediatr Infect Dis J. 2015 Jul;34(7):e169-75. doi: 10.1097/INF.0000000000000712.

3.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

5.

Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.

Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, Read JS, Stuard E, Rathore M, Mendez HA, Watts DH; Pediatric HIV/AIDS Cohort Study.

JAMA Pediatr. 2015 Jan;169(1):48-55. doi: 10.1001/jamapediatrics.2014.1889.

6.

Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis.

Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ.

Obstet Gynecol. 2000 Feb;95(2):167-73.

PMID:
10674574
7.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
8.

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium.

Pediatrics. 2007 Apr;119(4):e900-6. Epub 2007 Mar 12.

PMID:
17353299
9.

Antiretroviral use during pregnancy for treatment or prophylaxis.

Sturt AS, Read JS.

Expert Opin Pharmacother. 2011 Aug;12(12):1875-85. doi: 10.1517/14656566.2011.584062. Epub 2011 May 3. Review.

PMID:
21534886
10.

Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.

[No authors listed]

MMWR Recomm Rep. 1998 Jan 30;47(RR-2):1-30. Erratum in: MMWR Morb Mortal Wkly Rep 1998 Apr 24;47(15):315. MMWR Morb Mortal Wkly Rep 1998 Apr 17;47(14):287.

11.

Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women.

Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW.

Med Care. 2000 Sep;38(9):911-25.

PMID:
10982113
12.

Prevention of mother to child HIV transmission.

Duran AS, Ivalo SA, Hakim A, Masciottra FM, Zlatkes R, Adissi L, Neaton JD, Losso MH.

Medicina (B Aires). 2006;66(1):24-30.

PMID:
16555724
13.

The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program.

Palmsten K, Hernández-Díaz S, Chambers CD, Mogun H, Lai S, Gilmer TP, Huybrechts KF.

Obstet Gynecol. 2015 Sep;126(3):465-73. doi: 10.1097/AOG.0000000000000982.

PMID:
26244530
14.

Exposure to antiretroviral agents during pregnancy does not alter bone status in infants.

Mora S, Giacomet V, Viganò A, Cafarelli L, Stucchi S, Pivetti V, Manfredini V, Puzzovio M, Zuccotti G.

Bone. 2012 Jan;50(1):255-8. doi: 10.1016/j.bone.2011.10.030. Epub 2011 Nov 4.

PMID:
22080170
15.

Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance.

Sagna T, Bisseye C, Compaore TR, Kagone TS, Djigma FW, Ouermi D, Pirkle CM, Zeba MT, Bazie VJ, Douamba Z, Moret R, Pietra V, Koama A, Gnoula C, Sia JD, Nikiema JB, Simpore J.

Glob Health Action. 2015 Jan 27;8:26065. doi: 10.3402/gha.v8.26065. eCollection 2015.

16.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

17.

Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.

Tsague L, Tsiouris FO, Carter RJ, Mugisha V, Tene G, Nyankesha E, Koblavi-Deme S, Mugwaneza P, Kayirangwa E, Sahabo R, Abrams EJ.

BMC Public Health. 2010 Dec 6;10:753. doi: 10.1186/1471-2458-10-753.

18.

Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort.

Peters V, Liu KL, Dominguez K, Frederick T, Melville S, Hsu HW, Ortiz I, Rakusan T, Gill B, Thomas P.

Pediatrics. 2003 May;111(5 Pt 2):1186-91.

PMID:
12728136
19.

HIV prevalence and clinical care for HIV-positive pregnant women in Slovakia.

Peskova Z, Chabada J, Hinst P, Jarcuska P, Mokras M, Gabriskova S, Vachalikova M, Stanekova D, Greksova K.

Bratisl Lek Listy. 2009;110(12):777-81.

PMID:
20196472
20.

First trimester exposure to antiretroviral therapy and risk of birth defects.

Phiri K, Hernandez-Diaz S, Dugan KB, Williams PL, Dudley JA, Jules A, Callahan ST, Seage GR 3rd, Cooper WO.

Pediatr Infect Dis J. 2014 Jul;33(7):741-6. doi: 10.1097/INF.0000000000000251.

Items per page

Supplemental Content

Write to the Help Desk